CJ
PACB icon

Caitlin John’s Pacific Biosciences PACB Stock Holding History

Caitlin John’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-125
Closed -$469 – 918
2024
Q1 		$469 Hold
125
– – ﹤0.01% 807
2023
Q4 		$1.23K Buy
+125
New +$1.02K ﹤0.01% 744

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Caitlin John's PACB Position: Q2 2024 in Review

Caitlin John sold out of Pacific Biosciences (PACB) in Q2 2024, closing a stake of 125 shares — an estimated $469 sold.

Caitlin John first reported a position in PACB in Q4 2023 and held it in 2 quarters. The position peaked at $1.23K in Q4 2023. 228 funds tracked by Wall St. Rank hold PACB as of Q2 2024.

  • Caitlin John reported no remaining Pacific Biosciences position as of Q2 2024 after selling out during the quarter.
  • Caitlin John sold 125 Pacific Biosciences shares in Q2 2024, an estimated $469.
  • Caitlin John first reported a position in Pacific Biosciences in Q4 2023 and held it in 2 quarters.
  • Caitlin John's Pacific Biosciences position peaked at $1.23K in Q4 2023.
  • 228 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2024.

Based on Caitlin John's 13F filing for Q2 2024, filed 27 Jan 2025.